Biotech Showcase 2019: F2G Accelerates Phase IIb Program Vs Life-Threatening Fungal Infections
Executive Summary
Ian Nicholson, CEO of F2G, updated Mike Ward during Biotech Showcase 2019 on the progress the biotech company is having with its orotomide compound olorofim in a global open-label study for difficult-to-treat invasive fungal mold infections.